Obstructive Sleep Apnea Syndrome and Attention Executive Function Disturbances

This study is not yet open for participant recruitment.

Verified by Assaf-Harofeh Medical Center, September 2008

First Received: September 21, 2008 No Changes Posted

Sponsored by:	Assaf-Harofeh Medical Center
Information provided by:	Assaf-Harofeh Medical Center
ClinicalTrials.gov Identifier:	NCT00757796

Purpose

Studies demonstrate that sleep disturbances are associated with cognitive dysfunction and attention deficit.

However the correlation between the severity of obstructive sleep apnea and the degree of cognitive dysfunction was not demonstrated. Our hypothesis is that patients suffering from a more severe sleep apnea will demonstrate a greater degree of cognitive dysfunction.

Condition
Obstructive Sleep Apnea

Study Type:	Observational
Study Design:	Cohort, Prospective
Official Title:	Obstructive Sleep Apnea Syndrome and Attention Executive Function Disturbances

Resource links provided by NLM:

MedlinePlus related topics: Sleep Apnea

U.S. FDA Resources

Further study details as provided by Assaf-Harofeh Medical Center:

Estimated Enrollment:	80
Study Start Date:	October 2008

Detailed Description:

Studies demonstrate that sleep disturbances are associated with cognitive dysfunction and attention deficit.

However the correlation between the severity of sleep disturbances and the degree of cognitive dysfunction was not demonstrated.We intend to study 80 patients with various degrees of obstructive sleep apnea. All patients will undergo executive cognitive tests as well as tests to assess for levels of depression, anxiety and attention.

Eligibility

Ages Eligible for Study:	20 Years to 70 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Probability Sample

Study Population

Patients aged 20 - 70 years with obstructive sleep apnea.

Criteria

Inclusion Criteria:

Apnea hypopnea index>5
Age 20 - 70 years

Exclusion Criteria:

Pregnant women
Known chronic cardiovascular or pulmonary disease
Patients s/p CVA or brain damage
Known depression or other psychiatric disorder
Patients with severe cognitive dysfunction (MMSE<25)
Patients receiving stimulants, antipsychotic or anti-depression medications

Contacts and Locations

No Contacts or Locations Provided

More Information

No publications provided

Responsible Party:	The Sleep Laboratory, Assaf Harofeh Medical Center, Zerifin, Israel ( Itzhak Shpirer )
Study ID Numbers:	143/06
Study First Received:	September 21, 2008
Last Updated:	September 21, 2008
ClinicalTrials.gov Identifier:	NCT00757796 History of Changes
Health Authority:	Israel: Ethics Commission

Study placed in the following topic categories:

Signs and Symptoms
Sleep Apnea Syndromes
Respiratory Tract Diseases
Apnea
Respiration Disorders

Sleep Apnea, Obstructive
Dyssomnias
Sleep Disorders
Signs and Symptoms, Respiratory
Sleep Disorders, Intrinsic

Additional relevant MeSH terms:

Signs and Symptoms
Sleep Apnea Syndromes
Respiratory Tract Diseases
Apnea
Nervous System Diseases
Respiration Disorders

Sleep Apnea, Obstructive
Sleep Disorders
Dyssomnias
Signs and Symptoms, Respiratory
Sleep Disorders, Intrinsic

ClinicalTrials.gov processed this record on September 10, 2009